Overview

EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Status:
RECRUITING

Trial end date:
2028-04-30

Target enrollment:

Participant gender:

Summary

This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.

Phase:

PHASE1

Details

Lead Sponsor:

Grey Wolf Therapeutics

Treatments:

cemiplimab